ArticleBMC veterinary research2025
Comparative bioavailability study of two oral formulations of amoxicillin-clavulanic acid in healthy dogs.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmoxicillin-clavulanic acid combination (AMX-CA) is a widely used oral antibiotic for companion animals. In Thailand, various AMX-CA formulations are available. This study aimed to evaluate and compare the pharmacokinetic profiles and relative bioavailability of two AMX-CA formulations using a randomized, two-period, two-treatment crossover design in six healthy Beagle dogs. Each dog received a 250 mg AMX-CA tablet (formulation A or B) at a dosage of 20.5 ± 2.5 mg/kg, with a 7-day washout period between treatments. Blood samples were collected over a 24-h period post-administration, then AMX and CA concentrations were measured using LC-MS/MS. Bioequivalence was assessed based on the 90% confidence intervals (CI) for peak plasma concentration (C
resultsThe relative bioavailability of formulation B was 76.5% for AMX and 72.7% for CA, compared to formulation A. Only CA's C
conclusionsBioequivalence between the two formulations was not established, indicating that these formulations are not interchangeable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.